A kind of medicine for treating diabetic retinopathy and preparation method thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for retinopathy and diabetes, applied in the field of biopharmaceuticals, can solve the problems of ineffective prevention of DR development, visual field damage, retinal detachment, etc.
Inactive Publication Date: 2016-03-23
广州花海药业股份有限公司
View PDF5 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0004] The basic principle of treating DR is to control blood sugar, but it cannot effectively prevent the development of DR
For the treatment of non-proliferative DR, the curative effect of chemical drugs such as doxium and aldose reductase inhibitors is not satisfactory; for proliferative DR, laser photocoagulation and vitrectomy are currently effective methods. It has a certain effect, but it also has certain limitations, and there are serious consequences such as visual field damage and omentum detachment
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0019] Contents Prescription
[0020]
[0021] Capsule Prescription
[0022]
[0023] Preparation:
[0024] (1) Take the prescribed amount of soybean oil, beeswax and TBHQ, mix evenly, heat and melt, let cool to 40°C, add bilberry fruit extract and β-carotene in proportion by weight, stir slowly until uniform, and then grind through a colloid mill for 3 Once, make a suspension that is uniform and has a certain fluidity and cut-off property, cool naturally to room temperature, and set aside;
[0025] (2) Dissolve gelatin in water according to the weight ratio, make it fully swell, add glycerin and polyethylene glycol 400, stir evenly under vacuum, heat to 75°C to melt completely, and slowly release the vacuum in the pot , add ethylparaben and red iron oxide under continuous stirring, mix evenly, vacuumize and degas, keep warm, stand still, and set aside;
[0026] (3) Inject the glue solution prepared in step (2) into the equipment to form a two-layer adhesive tape. In ...
Embodiment 2
[0028] Contents Prescription
[0029]
[0030] Capsule Prescription
[0031]
[0032] Prepare according to the preparation method described in Example 1.
Embodiment 3
[0034] Contents Prescription
[0035]
[0036] Capsule Prescription
[0037]
[0038]
[0039] Prepare according to the preparation method described in Example 1.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a medicine for treating diabetic retinopathy and a preparation method of the medicine, and aims at providing a medicine which is precise in curative effect and good in medicine bioavailability and stability and is used for treating diabetic retinopathy. The medicine is characterized by comprising a softgel shell and content in the soft gel shell, wherein the content comprises the following components in parts by weight: 90-110 parts of bilberry fruit extract, 4-6 parts of beta renieratene, 4-20 parts of a suspending aid, 170-200 parts of a latent solvent and 0.01-0.06 part of an antioxidant; the softgel shell comprises the following components in parts by weight: 950-1050 parts of glutin, 950-1050 parts of water, 300-400 parts of a plasticizer, 45-55 parts of a disintegrant, 2.5-125 parts of a preservative and 3-15 parts of pigment. The medicine for treating diabetic retinopathy is precise in curative effect and good in medicine bioavailability and stability, and belongs to the technical field of bio-pharmaceuticals.
Description
technical field [0001] The invention relates to a medicine, in particular to a medicine for treating diabetic retinopathy and a preparation method thereof; it belongs to the technical field of biopharmaceuticals. Background technique [0002] Diabetic Retinopathy (Diabetic Retinopathy, DR) is the most common, serious and difficult eye complication of Diabetes Mellitus (DM), and one of the most common causes of blindness. Neurological complications, due to the destruction of the blood-retinal barrier, retinal capillary occlusion, non-perfusion zone formation, retinal microangioma, hemorrhage, exudation, and then neovascularization, vitreous hemorrhage, fiber proliferation and secondary retinal detachment , eventually leading to blindness. In the early stage of the disease, there may be no obvious ocular symptoms. As the disease progresses, vision loss, or sudden drop in vision, metamorphopsia, etc. may occur. If the treatment is not timely, it may lead to blindness. [0003...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more